Inclusion Criteria:  The patient is completely voluntary and has the ability to sign the research informed consent form within 30 days before enrollment; Age ≥18 years old and ≤65 years old; Pathologically confirmed cervical cancer; Those with IB3, IIA2, IIB, IIIA, IIIB, and those with cervical tumor ≥ 4cm or involved parametrial in IIIC1 and IIIC2 (FIGO 2018 staging); ECOG score 0-2 points; The complete blood count and basal metabolic indexes in the 14 days before enrollment must meet the following requirements: NEUT≥1.5*10^9/L, HGB≥80g/L, PLT≥100*10^9/L, blood creatinine < 1.5mg/dl (133umol/L), AST and ALT are within 2 times of the upper limit of normal; Those who have had regular bowel movements and had a negative stool routine test + occult blood before enrollment.  Exclusion Criteria:  Those who have a history of allergy to superoxide dismutase use; Patients with skin and mucous membrane infections, patients with obvious empyema or pelvic inflammatory disease; Those who have had chronic colitis, ulcerative colitis, and non-specific proctitis in the past; Those who have received cervical cancer surgery (including pelvic or retroperitoneal lymphadenectomy, excluding tumor biopsy), radiotherapy or chemotherapy; Those who are expected to be unable to receive brachytherapy, or brachytherapy needs to use tumor elimination, uterine tube inserted alone in one fraction, or template plan; Those who need to use fluorouracil or capecitabine or tigio in the concurrent chemotherapy regimen; History of other malignant tumors; Pregnant or lactating women; Accompanied by active infection and fever; Other serious diseases that may significantly affect the compliance of clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment.